Treatment of Patients With Acute Sinusitis

Bayer

Status: Completed

Conditions: Acute Bacterial Sinusitis

Treatments: Drug: Avelox (Moxifloxacin, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00930488

13207 - AX0601FR (Other Identifier)

TOPAS (Other Identifier)

12869 - AX0601EG (Other Identifier)

13166 - AX0601MY (Other Identifier)

13111 - AX0601RO (Other Identifier)

AX 0601 (Other Identifier)

12974 - AX0601SG (Other Identifier)

12868 - AX0601PK (Other Identifier)

12867 - AX0601AT (Other Identifier)

12973 - AX0601SK (Other Identifier)

13065 - AX0601CN (Other Identifier)

13026 - AX0601ID (Other Identifier)

13046 - AX0601PH (Other Identifier)

12870 - AX0601NL (Other Identifier)

12803

Details and patient eligibility

About

For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.

Enrollment: 6,777 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.

Exclusion criteria

• Those specified in the local product information - contraindications and precautions must be considered.

Trial design

6,777 participants in 1 patient group

Group 1

Treatment:

Drug: Avelox (Moxifloxacin, BAY12-8039)